loading
Schlusskurs vom Vortag:
$1.09
Offen:
$1.07
24-Stunden-Volumen:
40,207
Relative Volume:
0.01
Marktkapitalisierung:
$11.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.66M
KGV:
-0.1324
EPS:
-8.156
Netto-Cashflow:
$-11.09M
1W Leistung:
-6.12%
1M Leistung:
-16.95%
6M Leistung:
-56.47%
1J Leistung:
-61.99%
1-Tages-Spanne:
Value
$1.07
$1.09
1-Wochen-Bereich:
Value
$1.07
$1.20
52-Wochen-Spanne:
Value
$0.9657
$9.79

Phio Pharmaceuticals Corp Stock (PHIO) Company Profile

Name
Firmenname
Phio Pharmaceuticals Corp
Name
Telefon
(508) 767-3861
Name
Adresse
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Name
Mitarbeiter
5
Name
Twitter
@phio_pharma
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
PHIO's Discussions on Twitter

Vergleichen Sie PHIO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PHIO
Phio Pharmaceuticals Corp
1.0798 11.73M 0 -11.66M -11.09M -8.156
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.38 115.62B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
743.52 79.10B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
849.50 52.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
396.00 51.72B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
INSM
Insmed Inc
200.72 42.00B 447.02M -1.18B -906.14M -6.1812

Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-05 Fortgesetzt H.C. Wainwright Buy
2020-08-05 Eingeleitet H.C. Wainwright Buy

Phio Pharmaceuticals Corp Aktie (PHIO) Neueste Nachrichten

pulisher
Dec 06, 2025

EBIT per share of Phio Pharmaceuticals Corp. – BER:44R1 - TradingView

Dec 06, 2025
pulisher
Dec 05, 2025

Will Phio Pharmaceuticals Corp. (44R1) stock beat revenue estimatesMarket Performance Summary & Risk Managed Trade Strategies - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

How Phio Pharmaceuticals Corp. (44R1) stock reacts to fiscal policiesJuly 2025 Update & AI Optimized Trading Strategy Guides - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

How Phio Pharmaceuticals Corp. (44R1) stock reacts to new regulationsJuly 2025 Selloffs & High Yield Equity Trading Tips - Newser

Dec 05, 2025
pulisher
Dec 05, 2025

What technical patterns form on Phio Pharmaceuticals Corp. (44R1) stock chartsJuly 2025 Selloffs & High Yield Equity Trading Tips - Newser

Dec 05, 2025
pulisher
Dec 04, 2025

Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Dec 04, 2025
pulisher
Dec 04, 2025

Will Phio Pharmaceuticals Corp. (44R1) stock rise with strong economyWeekly Trend Summary & Weekly High Return Stock Opportunities - Newser

Dec 04, 2025
pulisher
Dec 04, 2025

Phio Pharma (PHIO) Stock Analysis Report | Financials & Insights - Benzinga

Dec 04, 2025
pulisher
Dec 02, 2025

How Phio Pharmaceuticals Corp. (44R1) stock compares with market leadersPortfolio Update Summary & Reliable Entry Point Trade Alerts - Newser

Dec 02, 2025
pulisher
Dec 02, 2025

What insider trading reveals about Phio Pharmaceuticals Corp. stockProfit Target & Verified Swing Trading Watchlists - Newser

Dec 02, 2025
pulisher
Dec 02, 2025

Can Phio Pharmaceuticals Corp. stock continue upward trendMarket Sentiment Report & Real-Time Volume Analysis - Newser

Dec 02, 2025
pulisher
Nov 30, 2025

Phio Pharmaceuticals Completes Enrollment for PH-762 Trial - MSN

Nov 30, 2025
pulisher
Nov 30, 2025

Why retail investors pile into Phio Pharmaceuticals Corp. stockLayoff News & Low Drawdown Trading Strategies - BỘ NỘI VỤ

Nov 30, 2025
pulisher
Nov 28, 2025

MSN Money - MSN

Nov 28, 2025
pulisher
Nov 27, 2025

How Phio Pharmaceuticals Corp. stock responds to policy changesMarket Risk Report & Fast Gain Swing Alerts - moha.gov.vn

Nov 27, 2025
pulisher
Nov 26, 2025

TARC Limited Earnings Review What Investors Need to KnowMid Cap Growth Trends & Free Risk Assessment and Control - earlytimes.in

Nov 26, 2025
pulisher
Nov 25, 2025

Phio Pharmaceuticals Completes Enrollment in Phase 1b Trial of PH-762 - TradingView — Track All Markets

Nov 25, 2025
pulisher
Nov 25, 2025

Phio Pharmaceuticals Corp. Announces Completion of Enrollment in Phase 1B Clinical Trial of Intasyl Sirna Lead Compound Ph-762 - marketscreener.com

Nov 25, 2025
pulisher
Nov 25, 2025

Phio completes enrollment in Phase 1b trial of skin cancer therapy - Investing.com Australia

Nov 25, 2025
pulisher
Nov 25, 2025

Phio completes enrollment in Phase 1b trial of skin cancer therapy By Investing.com - Investing.com South Africa

Nov 25, 2025
pulisher
Nov 25, 2025

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 - Newsfile

Nov 25, 2025
pulisher
Nov 25, 2025

Phio Pharmaceuticals (NASDAQ: PHIO) Reports PH-762 Data With 6 Complete Responses - Stock Titan

Nov 25, 2025
pulisher
Nov 24, 2025

[Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity - Stock Titan

Nov 24, 2025
pulisher
Nov 24, 2025

It is Poised to be a Bull Market for Phio Pharmaceuticals Corp (PHIO) - Setenews

Nov 24, 2025
pulisher
Nov 24, 2025

What is HC Wainwright’s Forecast for PHIO FY2025 Earnings? - Defense World

Nov 24, 2025
pulisher
Nov 21, 2025

How higher bond yields impact Phio Pharmaceuticals Corp. (44R1) stockJuly 2025 Closing Moves & Smart Swing Trading Alerts - newser.com

Nov 21, 2025
pulisher
Nov 20, 2025

Developing predictive dashboards with Phio Pharmaceuticals Corp. dataQuarterly Earnings Summary & Reliable Intraday Trade Alerts - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Phio Pharmaceuticals Corp files for offering of up to 11.8 million common shares by the Selling StockholdersSEC filing - MarketScreener

Nov 20, 2025
pulisher
Nov 20, 2025

[S-3] Phio Pharmaceuticals Corp. Shelf Registration Statement | PHIO SEC FilingForm S-3 - Stock Titan

Nov 20, 2025
pulisher
Nov 20, 2025

How Phio Pharmaceuticals Corp. (44R1) stock trades under stagflationMarket Activity Recap & AI Optimized Trade Strategies - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Published on: 2025-11-20 05:56:20 - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

How Phio Pharmaceuticals Corp. stock performs in rate cut cyclesPortfolio Value Summary & Real-Time Stock Entry Alerts - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

Is Phio Pharmaceuticals Corp. (44R1) stock protected from inflationJuly 2025 Analyst Calls & Low Risk Investment Opportunities - newser.com

Nov 20, 2025
pulisher
Nov 20, 2025

How Phio Pharmaceuticals Corp. (44R1) stock trades in high volatilityEarnings Summary Report & Accurate Entry/Exit Alerts - newser.com

Nov 20, 2025
pulisher
Nov 19, 2025

Published on: 2025-11-19 20:52:55 - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Published on: 2025-11-19 18:13:16 - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Published on: 2025-11-19 16:59:54 - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Published on: 2025-11-19 16:50:52 - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

How Phio Pharmaceuticals Corp. (44R1) stock correlates with oil marketsDay Trade & Free Risk Controlled Daily Trade Plans - newser.com

Nov 19, 2025
pulisher
Nov 19, 2025

Insider Buying: Robert Bitterman Acquires Additional Shares of P - GuruFocus

Nov 19, 2025
pulisher
Nov 19, 2025

Bitterman buys Phio Pharmaceuticals (PHIO) stock worth $6350 By Investing.com - Investing.com Canada

Nov 19, 2025
pulisher
Nov 19, 2025

Bitterman buys Phio Pharmaceuticals (PHIO) stock worth $6350 - Investing.com India

Nov 19, 2025

Finanzdaten der Phio Pharmaceuticals Corp-Aktie (PHIO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Phio Pharmaceuticals Corp-Aktie (PHIO) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Bitterman Robert J
Chairman, Pres. & CEO
Nov 18 '25
Buy
1.27
5,000
6,350
276,421
Bitterman Robert J
Chairman, Pres & CEO
Jun 10 '25
Buy
2.42
2,000
4,840
27,149
Ferrara Robert L
Director
Jun 10 '25
Buy
2.42
2,500
6,050
15,666
Bitterman Robert J
Chairman, Pres & CEO
Jun 09 '25
Buy
2.75
1,500
4,125
25,149
Bitterman Robert J
Chairman, Pres & CEO
May 21 '25
Buy
1.77
3,000
5,310
22,449
Bitterman Robert J
Chairman, Pres & CEO
May 22 '25
Buy
1.78
1,200
2,136
23,649
Ferrara Robert L
Director
May 20 '25
Buy
1.82
2,500
4,550
13,166
$38.53
price up icon 0.42%
$98.38
price down icon 0.32%
$31.57
price up icon 0.83%
$93.57
price down icon 0.31%
biotechnology ONC
$300.09
price down icon 5.87%
$196.92
price down icon 1.22%
Kapitalisierung:     |  Volumen (24h):